Medigene AG (ETR:MDG1 – Get Free Report)’s stock price rose 21.8% during mid-day trading on Tuesday . The stock traded as high as €2.06 ($2.14) and last traded at €1.90 ($1.98). Approximately 77,503 shares changed hands during trading, a decline of 75% from the average daily volume of 306,207 shares. The stock had previously closed at €1.56 ($1.63).
Medigene Stock Performance
The firm has a market cap of $28.01 million, a PE ratio of -1.57, a PEG ratio of 7.12 and a beta of 0.84. The business has a 50-day simple moving average of €1.20 and a 200 day simple moving average of €1.45. The company has a debt-to-equity ratio of 12.94, a current ratio of 2.39 and a quick ratio of 5.85.
About Medigene
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Featured Articles
- Five stocks we like better than Medigene
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- There Are Different Types of Stock To Invest In
- What Does the Future Hold for Eli Lilly?
- What is the NASDAQ Stock Exchange?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
